Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention

Posted September 6, 2011 More

Yeh RW, Normand S-LT, Wolf RE, Jones PG, Ho KKL, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA.
Circulation, Year: 2011, Volume: DOI: 10.1161/CIRCULATIONAHA.111.045229.

Link to publication

Background: Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting DES use in patients at the highest risk for target vessel revascularization (TVR), we developed and validated a model to predict TVR.

Conclusions: A predictive model using commonly collected variables can identify patients who may derive the greatest benefit in TVR reduction from DES. Whether use of the model improves the safety and cost-effectiveness of DES use should be tested prospectively.

 

Category: 2011, Publication